Aurinia Pharmaceuticals (AUPH)
In a report issued on August 12, Douglas Miehm from RBC Capital maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $20.00. The company’s shares closed last Thursday at $14.17.
According to TipRanks.com, Miehm has 0 stars on 0-5 stars ranking scale with an average return of -7.3% and a 37.7% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Oncolytics Biotech, and Medical Facilities.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $25.83 average price target, representing an 81.5% upside. In a report issued on August 11, Oppenheimer also maintained a Buy rating on the stock with a $22.00 price target.
Fresenius Medical Care (FMS)
In a report issued on August 12, Frank Morgan from RBC Capital maintained a Hold rating on Fresenius Medical Care, with a price target of $43.00. The company’s shares closed last Thursday at $43.15.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 12.5% and a 65.5% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Genesis Healthcare, Acadia Healthcare, and Encompass Health.
Currently, the analyst consensus on Fresenius Medical Care is a Moderate Buy with an average price target of $42.45, representing a -1.6% downside. In a report issued on August 5, Jefferies also downgraded the stock to Hold with a $40.10 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.